Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR2 | P41597 | 9/20 | 0.49 |
| ▸ | PTGER4 | P35408 | 6/20 | 0.47 |
| ▸ | PTGDR | Q13258 | 4/20 | 0.47 |
| ▸ | CYP3A5 | P20815 | 1/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.41 |
| ▸ | CACNA1I | Q9P0X4 | 1/20 | 0.41 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.40 |
| ▸ | PTGER1 | P34995 | 1/20 | 0.40 |
| ▸ | PTGFR | P43088 | 1/20 | 0.40 |
| ▸ | PTGER3 | P43115 | 1/20 | 0.40 |
| ▸ | PTGER2 | P43116 | 1/20 | 0.40 |
| ▸ | VCP | P55072 | 1/20 | 0.38 |
| ▸ | MMP12 | P39900 | 1/20 | 0.38 |
| ▸ | CNR2 | P34972 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12584009 | 0.91 | CCR2 (0.47) | CCR2PTGER4PTGDRCYP3A5KCNH2 | |
| SCHEMBL12585483 | 0.89 | PTGER4 (0.45) | CCR2PTGER4PTGDRVCPMMP12 | |
| SCHEMBL12948746 | 0.89 | PTGER4 (0.45) | CCR2PTGER4PTGDRKCNH2CACNA1I | |
| SCHEMBL12585950 | 0.88 | PTGER4 (0.42) | CCR2PTGER4PTGDRCYP3A5CNR2 | |
| SCHEMBL988831 | 0.87 | VCP (0.43) | CCR2PTGER4PTGDRKCNH2CACNA1I | |
| SCHEMBL987833 | 0.87 | CCR2 (0.47) | CCR2PTGER4PTGDRCYP3A5KCNH2 | |
| SCHEMBL988090 | 0.87 | PTGER4 (0.41) | CCR2PTGER4PTGDRCYP3A5KCNH2 | |
| SCHEMBL12585911 | 0.86 | PTGER4 (0.43) | CCR2PTGER4PTGDRCYP3A5KCNH2 | |
| SCHEMBL12585935 | 0.85 | PTGER4 (0.43) | CCR2PTGER4PTGDRCYP3A5TBXA2R | |
| SCHEMBL12585974 | 0.85 | PTGER4 (0.43) | CCR2PTGER4PTGDRCYP3A5MMP12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8598355-B2 | Amide compound | ASTELLAS PHARMA INC. (JP) | 2013-12-03 | — | — | US | disclosed |
| EP-2565191-A1 | 4-(Indol-7-ylcarbonylaminomethyl)cyclohexanecarboxylic acid derivatives as EP4 receptor antagonists useful for the treatment of chronic renal failure or diabetic nephropathy | Astellas Pharma Inc. (JP) | 2013-03-06 | — | — | EP | disclosed |
| US-20110144153-A1 | AMIDE COMPOUND | ASTELLAS PHARMA INC. (JP) | 2011-06-16 | — | — | US | disclosed |
| US-20110144153-A1 | AMIDE COMPOUND | ASTELLAS PHARMA INC. (JP) | 2011-06-16 | — | — | US | disclosed |
| US-20110144153-A1 | AMIDE COMPOUND | ASTELLAS PHARMA INC. (JP) | 2011-06-16 | — | — | US | disclosed |
| EP-2277858-A1 | AMIDE COMPOUND | Astellas Pharma Inc. (JP) | 2011-01-26 | — | — | EP | disclosed |
| WO-2009139373-A1 | AMIDE COMPOUND | アステラス製薬株式会社 (JP) | 2009-11-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110144153-A1 | AMIDE COMPOUND | PTGER4, PTGER1, PTGER2 | CCR2 385/4885PTGER4 1/4885PTGDR 13/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.